



Pembrolizumab (Keytruda®)

Lungenkarzinom, nicht-kleinzellig (NSCLC) » Nicht-Plattenepithelkarzinom, Kombination » Erstlinie

Empfehlungen der Fachgesellschaft zum Einsatz neuer Arzneimittel

Herausgeber

DGHO Deutsche Gesellschaft für Hämatologie und
Medizinische Onkologie e.V.
Bauhofstr. 12
10117 Berlin

Geschäftsführender Vorsitzender: Prof. Dr. med. Andreas Hochhaus

Telefon: +49 (0)30 27 87 60 89 - 0

info@dgho.de

www.dgho.de

Ansprechpartner

Prof. Dr. med. Bernhard Wörmann
Medizinischer Leiter

Quelle

www.onkopedia.com

Die Empfehlungen der DGHO für die Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen entbinden die verantwortliche Ärztin / den verantwortlichen Arzt nicht davon, notwendige Diagnostik, Indikationen, Kontraindikationen und Dosierungen im Einzelfall zu überprüfen! Die DGHO übernimmt für Empfehlungen keine Gewähr.

Inhaltsverzeichnis

1 Pembrolizumab, NSCLC, non-squamous, combination, first line	... 2
--	--------------

Pembrolizumab (Keytruda®)

Dokument: Fact Sheet

Spezifizierung: Lungenkarzinom, nicht-kleinzellig (NSCLC) » Nicht-Plattenepithelkarzinom, Kombination » Erstlinie

Stand: Juli 2021

1 Pembrolizumab, NSCLC, non-squamous, combination, first line

Pembrolizumab, NSCLC, non-squamous, combination, first line																								
onkopedia		Facts	Appraisal																					
		EU Approval 2019																						
Parameter	Results¹⁴	HR¹⁵	p value																					
RR ²	18.4 vs 47.6																							
PFS ³	4.9 vs 8.8	0.48	p < 0.001																					
OS ⁵	10.7 vs 22.0	0.56	p < 0.001																					
SAE ⁷	65.8 vs 67.2																							
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 10%;"></td> <td style="width: 10%;">5</td> <td style="width: 10%;">4</td> <td style="width: 10%;">3b</td> <td style="width: 10%;">3a</td> <td style="width: 10%;">2c</td> <td style="width: 10%;">2b</td> <td style="width: 10%;">2a</td> <td style="width: 10%;">1b</td> <td style="width: 10%;">1a</td> </tr> <tr> <td>Evidence (LoE)</td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> </tr> </table>					5	4	3b	3a	2c	2b	2a	1b	1a	Evidence (LoE)										
	5	4	3b	3a	2c	2b	2a	1b	1a															
Evidence (LoE)																								
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%;"></td> <td style="width: 20%;">1</td> <td style="width: 20%;">2</td> <td style="width: 20%;">3</td> <td style="width: 20%;">4</td> <td style="width: 20%;">5</td> </tr> <tr> <td>Clinical benefit (ESMO MCBS)</td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: yellow;"></td> <td style="background-color: #cccccc;"></td> </tr> </table>					1	2	3	4	5	Clinical benefit (ESMO MCBS)														
	1	2	3	4	5																			
Clinical benefit (ESMO MCBS)																								
<div style="display: flex; justify-content: center; gap: 10px;"> ■ curative ■ non-curative </div>																								
Patients first line, non squamous Trial KEYNOTE-189, phase 3 Randomisation 1 : 1 N¹ 616 New Therapy Platin + Pemetrexed Control Platin + Pemetrexed + Pembrolizumab Publication DOI:10.1056/NEJMoa1801005		Additional benefit (G-BA) <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 10%;"></td> <td style="width: 10%;">lower</td> <td style="width: 10%;">proven</td> <td style="width: 10%;">not quantifiable</td> <td style="width: 10%;">not minor</td> <td style="width: 10%;">considerable</td> <td style="width: 10%;">major</td> </tr> <tr> <td>PD-L1 <50%</td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> <tr> <td>PD-L1 ≥50%</td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> </table>			lower	proven	not quantifiable	not minor	considerable	major	PD-L1 <50%							PD-L1 ≥50%						
	lower	proven	not quantifiable	not minor	considerable	major																		
PD-L1 <50%																								
PD-L1 ≥50%																								

Legende:

¹ N - number of patients

² RR - remission rate, in %

³ PFS - progression-free survival in months

⁵ OS - overall survival in months

⁷ SAE - serious adverse events, CTCAE grade 3/4

¹⁴ results for control, results for new therapy

¹⁵ hazard ratio for new therapy